• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

TICAM-1/TRIF 与 Act1 结合并抑制 IL-17 受体介导的炎症反应。

TICAM-1/TRIF associates with Act1 and suppresses IL-17 receptor-mediated inflammatory responses.

机构信息

Department of Immunology, Graduate School of Medical Sciences, Faculty of Life Sciences, Kumamoto University, 1-1-1 Honjo, Kumamoto, Japan.

Department of Pediatrics, Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjo, Kumamoto, Japan.

出版信息

Life Sci Alliance. 2021 Nov 24;5(2). doi: 10.26508/lsa.202101181. Print 2022 Feb.

DOI:10.26508/lsa.202101181
PMID:34819358
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8616538/
Abstract

TICAM-1 (also called TRIF) is the sole adaptor of TLR3 that recognizes double-stranded RNA. Here, we report that TICAM-1 is involved not only in TLR3 signaling but also in the cytokine receptor IL-17RA signaling. We found that TICAM-1 bound to IL-17R adaptor Act1 to inhibit the interaction between IL-17RA and Act1. Interestingly, knockout promoted IL-17RA/Act1 interaction and increased IL-17A-mediated activation of NF-κB and MAP kinases, leading to enhanced expression of inflammatory cytokines and chemokines upon IL-17A stimulation. Moreover, knockout augmented IL-17A-mediated CXCL1 and CXCL2 expression in vivo, resulting in accumulation of myeloid cells. Furthermore, knockout enhanced delayed type hypersensitivity and exacerbated experimental autoimmune encephalomyelitis. knockout promoted accumulation of myeloid and lymphoid cells in the spinal cord of EAE-induced mice. Collectively, these data indicate that TICAM-1 inhibits the interaction between IL-17RA and Act1 and functions as a negative regulator in IL-17A-mediated inflammatory responses.

摘要

TICAM-1(也称为 TRIF)是唯一识别双链 RNA 的 TLR3 衔接蛋白。在这里,我们报告 TICAM-1 不仅参与 TLR3 信号转导,还参与细胞因子受体 IL-17RA 信号转导。我们发现 TICAM-1 与 IL-17R 衔接子 Act1 结合,抑制 IL-17RA 和 Act1 之间的相互作用。有趣的是, 缺失促进了 IL-17RA/Act1 相互作用,并增加了 IL-17A 介导的 NF-κB 和 MAP 激酶的激活,导致在 IL-17A 刺激下炎症细胞因子和趋化因子的表达增强。此外, 缺失增强了体内 IL-17A 介导的 CXCL1 和 CXCL2 的表达,导致髓样细胞的积累。此外, 缺失增强了迟发型超敏反应并加重了实验性自身免疫性脑脊髓炎。 缺失促进了 EAE 诱导的小鼠脊髓中髓样细胞和淋巴样细胞的积累。总之,这些数据表明 TICAM-1 抑制了 IL-17RA 和 Act1 之间的相互作用,并作为 IL-17A 介导的炎症反应的负调节剂发挥作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8816/8616538/e81c8155cb95/LSA-2021-01181_Fig6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8816/8616538/a87404e45b28/LSA-2021-01181_FigS1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8816/8616538/5ee6ed46bf02/LSA-2021-01181_Fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8816/8616538/bc03e12cddfa/LSA-2021-01181_FigS2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8816/8616538/79b9753dacdd/LSA-2021-01181_Fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8816/8616538/efd14761886f/LSA-2021-01181_Fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8816/8616538/ba686bfe74b8/LSA-2021-01181_FigS3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8816/8616538/a82f85dcedad/LSA-2021-01181_Fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8816/8616538/45af6207ab76/LSA-2021-01181_FigS4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8816/8616538/14d159bf6a7f/LSA-2021-01181_Fig5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8816/8616538/e81c8155cb95/LSA-2021-01181_Fig6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8816/8616538/a87404e45b28/LSA-2021-01181_FigS1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8816/8616538/5ee6ed46bf02/LSA-2021-01181_Fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8816/8616538/bc03e12cddfa/LSA-2021-01181_FigS2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8816/8616538/79b9753dacdd/LSA-2021-01181_Fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8816/8616538/efd14761886f/LSA-2021-01181_Fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8816/8616538/ba686bfe74b8/LSA-2021-01181_FigS3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8816/8616538/a82f85dcedad/LSA-2021-01181_Fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8816/8616538/45af6207ab76/LSA-2021-01181_FigS4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8816/8616538/14d159bf6a7f/LSA-2021-01181_Fig5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8816/8616538/e81c8155cb95/LSA-2021-01181_Fig6.jpg

相似文献

1
TICAM-1/TRIF associates with Act1 and suppresses IL-17 receptor-mediated inflammatory responses.TICAM-1/TRIF 与 Act1 结合并抑制 IL-17 受体介导的炎症反应。
Life Sci Alliance. 2021 Nov 24;5(2). doi: 10.26508/lsa.202101181. Print 2022 Feb.
2
TRAF6-dependent Act1 phosphorylation by the IκB kinase-related kinases suppresses interleukin-17-induced NF-κB activation.TRAF6 依赖性 Act1 磷酸化被 IκB 激酶相关激酶抑制,从而抑制白细胞介素-17 诱导的 NF-κB 激活。
Mol Cell Biol. 2012 Oct;32(19):3925-37. doi: 10.1128/MCB.00268-12. Epub 2012 Jul 30.
3
Interleukin-17A promotes MUC5AC expression and goblet cell hyperplasia in nasal polyps via the Act1-mediated pathway.白细胞介素-17A通过Act1介导的途径促进鼻息肉中MUC5AC的表达和杯状细胞增生。
PLoS One. 2014 Jun 3;9(6):e98915. doi: 10.1371/journal.pone.0098915. eCollection 2014.
4
Oligomerized TICAM-1 (TRIF) in the cytoplasm recruits nuclear BS69 to enhance NF-kappaB activation and type I IFN induction.细胞质中的寡聚化 TICAM-1(TRIF)募集核 BS69 以增强 NF-κB 激活和 I 型 IFN 诱导。
Eur J Immunol. 2009 Dec;39(12):3469-76. doi: 10.1002/eji.200939878.
5
Spatiotemporal mobilization of Toll/IL-1 receptor domain-containing adaptor molecule-1 in response to dsRNA.Toll/白细胞介素-1受体结构域含有的接头分子1响应双链RNA的时空动员
J Immunol. 2007 Nov 15;179(10):6867-72. doi: 10.4049/jimmunol.179.10.6867.
6
The TLR3/TICAM-1 signal constitutively controls spontaneous polyposis through suppression of c-Myc in Apc mice.TLR3/TICAM-1 信号通过抑制 Apc 小鼠中的 c-Myc 来持续控制自发性多发性息肉。
J Biomed Sci. 2017 Oct 17;24(1):79. doi: 10.1186/s12929-017-0387-z.
7
TICAM-1 is dispensable in STING-mediated innate immune responses in myeloid immune cells.TICAM-1 在髓系免疫细胞中 STING 介导的先天免疫反应中可有可无。
Biochem Biophys Res Commun. 2018 May 23;499(4):985-991. doi: 10.1016/j.bbrc.2018.04.035. Epub 2018 Apr 9.
8
14-3-3-zeta participates in TLR3-mediated TICAM-1 signal-platform formation.14-3-3-ζ参与Toll样受体3介导的TICAM-1信号平台形成。
Mol Immunol. 2016 May;73:60-8. doi: 10.1016/j.molimm.2016.03.010. Epub 2016 Apr 6.
9
A molecular mechanism for Toll-IL-1 receptor domain-containing adaptor molecule-1-mediated IRF-3 activation.Toll-IL-1 受体域包含衔接子分子-1 介导的 IRF-3 激活的分子机制。
J Biol Chem. 2010 Jun 25;285(26):20128-36. doi: 10.1074/jbc.M109.099101. Epub 2010 Apr 23.
10
Toll-like receptor 3-mediated activation of NF-kappaB and IRF3 diverges at Toll-IL-1 receptor domain-containing adapter inducing IFN-beta.Toll样受体3介导的核因子κB和干扰素调节因子3的激活在含Toll-白细胞介素-1受体结构域的接头诱导干扰素-β处出现分歧。
Proc Natl Acad Sci U S A. 2004 Mar 9;101(10):3533-8. doi: 10.1073/pnas.0308496101. Epub 2004 Feb 24.

引用本文的文献

1
Role of TLRs as signaling cascades to combat infectious diseases: a review.Toll样受体作为对抗传染病的信号级联反应的作用:综述
Cell Mol Life Sci. 2025 Mar 19;82(1):122. doi: 10.1007/s00018-025-05631-x.
2
Ultrarare Variants in DNA Damage Repair Genes in Pediatric Acute-Onset Neuropsychiatric Syndrome or Acute Behavioral Regression in Neurodevelopmental Disorders.小儿急性起病神经精神综合征或神经发育障碍急性行为倒退中DNA损伤修复基因的超罕见变异
Dev Neurosci. 2024 Oct 11:1-20. doi: 10.1159/000541908.
3
Characteristics of mucin hypersecretion in different inflammatory patterns based on endotypes of chronic rhinosinusitis.

本文引用的文献

1
Cytokine profile and disease severity in patients with COVID-19.COVID-19 患者的细胞因子谱与疾病严重程度。
Cytokine. 2021 Jan;137:155323. doi: 10.1016/j.cyto.2020.155323. Epub 2020 Sep 30.
2
MAIT cell activation and dynamics associated with COVID-19 disease severity.MAIT 细胞的激活与 COVID-19 疾病严重程度相关。
Sci Immunol. 2020 Sep 28;5(51). doi: 10.1126/sciimmunol.abe1670.
3
Inborn errors of type I IFN immunity in patients with life-threatening COVID-19.COVID-19 危重症患者的 I 型 IFN 免疫先天缺陷。
基于慢性鼻-鼻窦炎内型的不同炎症模式下黏蛋白高分泌的特征
Clin Transl Allergy. 2024 Jan;14(1):e12334. doi: 10.1002/clt2.12334.
4
Advances in the study of IL-17 in neurological diseases and mental disorders.白细胞介素-17在神经疾病和精神障碍研究中的进展
Front Neurol. 2023 Nov 16;14:1284304. doi: 10.3389/fneur.2023.1284304. eCollection 2023.
5
Mulberry Leaf Supplements Effecting Anti-Inflammatory Genes and Improving Obesity in Elderly Overweight Dogs.桑叶补充剂对老年超重犬抗炎基因的影响及改善肥胖作用。
Int J Mol Sci. 2022 Dec 2;23(23):15215. doi: 10.3390/ijms232315215.
6
Potential for TCDD to induce regulatory functions in B cells as part of the mechanism for T cell suppression in EAE.TCDD 诱导 B 细胞调节功能的潜力可能是 EAE 中 T 细胞抑制机制的一部分。
Toxicol Appl Pharmacol. 2022 Nov 1;454:116259. doi: 10.1016/j.taap.2022.116259. Epub 2022 Sep 28.
Science. 2020 Oct 23;370(6515). doi: 10.1126/science.abd4570. Epub 2020 Sep 24.
4
Immune responses to SARS-CoV-2 infection in hospitalized pediatric and adult patients.儿童和成年住院患者对 SARS-CoV-2 感染的免疫反应。
Sci Transl Med. 2020 Oct 7;12(564). doi: 10.1126/scitranslmed.abd5487. Epub 2020 Sep 21.
5
Pathological findings of COVID-19 associated with acute respiratory distress syndrome.与急性呼吸窘迫综合征相关的新型冠状病毒肺炎的病理表现
Lancet Respir Med. 2020 Apr;8(4):420-422. doi: 10.1016/S2213-2600(20)30076-X. Epub 2020 Feb 18.
6
Interleukin-17A Serves a Priming Role in Autoimmunity by Recruiting IL-1β-Producing Myeloid Cells that Promote Pathogenic T Cells.白细胞介素-17A 通过募集产生白细胞介素-1β 的髓样细胞来在自身免疫中发挥启动作用,从而促进致病性 T 细胞。
Immunity. 2020 Feb 18;52(2):342-356.e6. doi: 10.1016/j.immuni.2020.01.002. Epub 2020 Feb 4.
7
Somatic inflammatory gene mutations in human ulcerative colitis epithelium.人类溃疡性结肠炎上皮细胞中的体细胞炎症基因突变。
Nature. 2020 Jan;577(7789):254-259. doi: 10.1038/s41586-019-1844-5. Epub 2019 Dec 18.
8
IL-17 receptor-based signaling and implications for disease.IL-17 受体信号转导及其在疾病中的意义。
Nat Immunol. 2019 Dec;20(12):1594-1602. doi: 10.1038/s41590-019-0514-y. Epub 2019 Nov 19.
9
DDX23, an Evolutionary Conserved dsRNA Sensor, Participates in Innate Antiviral Responses by Pairing With TRIF or MAVS.DDX23,一种进化保守的 dsRNA 传感器,通过与 TRIF 或 MAVS 配对参与先天抗病毒反应。
Front Immunol. 2019 Sep 18;10:2202. doi: 10.3389/fimmu.2019.02202. eCollection 2019.
10
The IL-17 Family of Cytokines in Health and Disease.白细胞介素-17 细胞因子家族在健康和疾病中的作用。
Immunity. 2019 Apr 16;50(4):892-906. doi: 10.1016/j.immuni.2019.03.021.